Viewing Study NCT05058651


Ignite Creation Date: 2025-12-24 @ 11:57 PM
Ignite Modification Date: 2026-02-20 @ 6:39 PM
Study NCT ID: NCT05058651
Status: RECRUITING
Last Update Posted: 2025-12-24
First Post: 2021-09-25
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Sponsor: National Cancer Institute (NCI)
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Extrapulmonary Neuroendocrine Carcinoma View
None Metastatic Extrapulmonary Neuroendocrine Carcinoma View
None Recurrent Extrapulmonary Neuroendocrine Carcinoma View
None Unresectable Extrapulmonary Neuroendocrine Carcinoma View
Keywords: